Our data suggest that clinical features, laboratory findings and treatment responses in the pediatric T-ALL population do not differ according to the expression level of CRLF2 but that CRLF2 high expression at diagnosis can contribute to a high risk of relapse in pediatric T-ALL patients. Here, CRLF2 is linked to acute lymphoblastic leukemia.